Conditions: Patients With Advanced Ovarian Cancer Sensitive to Platinum-based Chemotherapy
Keywords: ovarian cancer chemotherapy sensitive ZD4054
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 120
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare progression-free survival in patients with advanced ovarian cancer treated with ZD4054 in combination with carboplatin+paclitaxel versus placebo in combination with carboplatin+paclitaxel.

Detailed description:

Arms:
arm 1: ZD4054 10mg oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks arm 2: Placebo oral tablet once daily + paclitaxel +carboplatin intravenous infusions every 3 weeks

Interventions: intervention 1: ZD4054 Zibotentan intervention 2: Paclitaxel intervention 3: Carboplatin intervention 4: Placebo
Intervention descriptions: intervention 1: 10 mg oral tablets once daily intervention 2: 175mg/m2 IV on day 1 every 3 weeks intervention 3: Carboplatin AUC of 5.0 IV on day 1 every 3 weeks intervention 4: matching placebo for ZD4054 10 mg

Protocol document: